Clinical Trial Update: GMZ2-Aluminum Hydroxide Phase I, Tübingen [Phase 1]

View source ↗

Summary

Phase I clinical trial update for the GMZ2 malaria vaccine with aluminum hydroxide in Tübingen; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malaria

Drugs mentioned

• GMZ2-Aluminum Hydroxide (GMZ2)

Snippet

Sponsor: European Vaccine Initiative | Conditions: Malaria | Phase 1 | Status: UNKNOWN